MedTrace Logo

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2017-10-16

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and the immune responses to the HIV vaccine candidate, MVA-CMDR. This vaccine was designed to induce immune responses to three HIV "passenger" genes encoded with the viral vector, MVA.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

MVA-CMDR

10\^7 PFU IM, 1.0 mL

BIOLOGICAL

Placebo

1.0 mL IM

BIOLOGICAL

MVA-CMDR

10\^6 PFU ID, 0.1 mL

BIOLOGICAL

Placebo

0.1 mL ID

BIOLOGICAL

MVA-CMDR

10\^8 PFU IM, 1.0 mL

BIOLOGICAL

MVA-CMDR

10\^7 PFD ID, 0.1 mL

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Mary Marovich, MD, DTM&H · US Military HIV Research Program

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00376090 on ClinicalTrials.gov